Wondering if we might be seeing a large investor about to underwrite phase 3 for her-vaxx.
realistically we either need to sell it in full or find some funds.
If the intention is to keep this through phase 3 in house then we will need a partner with deep pockets.
I would be favouring a non pharma related entity so that some form of independence is maintained which supports the “dance card” view of licensing the product to multiple pharmas.
my opinion only DYOR
Ann: Trading Halt, page-73
-
- There are more pages in this discussion • 342 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
